NEW combination trial arm of RMC-9805 plus RMC-6236
- fireflyannf
- Apr 7
- 2 min read
Changes to KRAS G12D trial - July 23, 2024
The monotherapy arm of RMC-9805 - RAS(ON) inhibitor
now includes info on the combination arm of RMC-9805 plus RMC-6236
Expansion to 17 US trial sites
290 to 444 patients
NCT06040541 trial listing
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
"This is an open-label, multicenter, Phase 1/1b study of RMC-9805, monotherapy, selective and orally bioavailable KRAS G12D(ON) inhibitor, in subjects with KRASG12D-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity. The study consists of two parts: Part 1- Dose-Exploration and Part 2- Dose-Expansion."
Phase 1 trial from Revolution Medicines, Inc.
Opened in September 2023, Enrolling in the US
Colorectal Cancer (CRC)
Advanced Solid Tumors (this would include Appendiceal)
Contact info
Name: Revolution Medicines, Inc.
Phone Number:(650) 779-2300
Email: CT-inquiries@RevMed.com
NOTE: All interventional trials involve risk, so please discuss with your oncology team. And ask questions of the researchers e.g. patient responses and any side effects on treatment.
Revolution Medicines - scientific presentation, May 2023
RAS(ON) Inhibitors - RMC-9805 (KRASG12D) - slides 18 – 22 (slide 18 pictured)
May 2024 - Revolution Medicines press release
“Expanding the reach of RMC-6236 monotherapy and/or combination regimens into earlier lines of therapy, RAS cancer genotypes beyond RAS G12X, and tumor types beyond NSCLC and PDAC. Objective responses have been observed in second and later line monotherapy treatment of patients with a range of solid tumor types carrying diverse RAS mutation variants. Exploratory clinical studies of several combinations have been initiated to inform potential options for studies in the first line (1L) treatment of metastatic or earlier stage cancers. “
